CRBU
HEALTHCARECaribou Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving CRBU Today?
No stock-specific AI insight has been generated for CRBU yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.95
Fundamentals
Trading
CRBU News
20 articles- Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Caribou Biosciences to Participate in the BofA Securities 2026 Health Care ConferenceYahoo Finance·May 5, 2026
- Discovering Whitehawk Therapeutics Among 3 Promising Penny StocksYahoo Finance·Apr 15, 2026
- Three Best Genomics Stocks for Your Portfolio in 2026Yahoo Finance·Apr 13, 2026
- Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 2, 2026
- Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell TherapyYahoo Finance·Mar 31, 2026
- Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?Yahoo Finance·Mar 26, 2026
- Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?Yahoo Finance·Mar 16, 2026
- Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink ConferenceMarketbeat·Mar 14, 2026
- Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 5, 2026
- Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 5, 2026
- EyePoint (EYPT) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 4, 2026
- Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 2, 2026
- Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 26, 2026
- Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 24, 2026
- Caribou Biosciences Details Pivotal-Ready Vispa-cel Plan, Flags Need for More Capital at Citi SummitMarketbeat·Feb 23, 2026
- Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear StreetYahoo Finance·Feb 20, 2026
- Genomics Stocks That Deserve a Place in Your Portfolio in 2026Yahoo Finance·Feb 20, 2026
- Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per SampleYahoo Finance·Feb 17, 2026
All 20 articles loaded
Price Data
52-Week Range
$1.95
Fundamentals
Trading
About Caribou Biosciences Inc
Caribou Biosciences Inc. is a pioneering biotechnology company leveraging advanced CRISPR technology to create transformative therapies for genetic disorders and oncology. With a robust pipeline of innovative product candidates, the company is dedicated to addressing significant unmet medical needs and enhancing the landscape of precision medicine. Caribou's strategic collaborations and focus on proprietary genome-editing solutions underscore its potential to redefine treatment approaches and deliver substantial benefits to patients, positioning it as a leader in the biopharmaceutical sector.